A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active thyroid eye disease, according to topline results from the REVEAL-1 trial.Elegrobart (Viridian Therapeutics) is a half-life exten…
A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active thyroid eye disease, according to topline results from the REVEAL-1 trial.Elegrobart (Viridian Therapeutics) is a half-life exten…
ALAMEDA, Calif.–(BUSINESS WIRE)–Science Corporation, the full-stack neural engineering and brain-computer interface (BCI) company focused on restoring and extending life, today announced the appointment of Murat Günel, MD, as Medical Director for Bra…
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
SYD-101 significantly slowed the progression of myopia in younger children and quick progressors over 36 months, according to a press release from Sydnexis.“The STAR trial provides compelling evidence that low-dose atropine can meaningfully slow myopia…